Atai Beckley N.V. (DE:B72)
XETRA:B72
Want to see DE:B72 full AI Analyst Report?
B72 Stock Chart & Stats
€3.64
-€0.07(-3.75%)
At close: 4:00 PM EST
€3.64
-€0.07(-3.75%)
Day’s Range― - ―
52-Week Range€1.19 - €6.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.49K
Market Cap
€1.32B
Enterprise Value€709.00M
Total Cash (Recent Filing)€256.04M
Total Debt (Recent Filing)€2.07M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding366,916,900
10 Day Avg. Volume2,487
30 Day Avg. Volume2,489
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.18
Price to Sales (P/S)226.59
P/FCF Ratio-8.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.66Price Target Upside247.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.41
Revenue Forecast (FY)€413.39K
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthThe company's low absolute debt and a materially improved equity base in 2025 provide durable financial flexibility. This reduces near-term refinancing risk, supports continued R&D investment and partner negotiations, and gives runway to execute clinical programs despite ongoing losses.
Asset-light Partnership PlatformAtai's platform model spreads development risk across partnered program entities and monetizes through upfronts, milestones and royalties. This structural business model creates optionality to fund programs without sole reliance on operating revenue, enabling scale of R&D with lower fixed commercial costs.
Pipeline Focus On Large Unmet NeedsFocusing on psychedelic-inspired and other novel mental‑health therapies targets large, structurally underserved markets. Durable demand for better mental‑health treatments and a differentiated scientific focus increase the long‑term commercial upside if clinical programs advance successfully.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow requires ongoing external financing to fund operations. That dependence raises dilution risk for shareholders, limits the company's ability to expand program breadth simultaneously, and constrains strategic agility if capital markets tighten.
Large And Volatile LossesBig, volatile operating and net losses reflect high development spend and one-time charges that impair returns. Persistent negative profitability dilutes equity value, can complicate partner negotiations, and may pressure management to prioritize certain programs over others, slowing long-term pipeline progress.
Minimal, Uneven RevenueThe company lacks meaningful recurring product revenue, making cash flows contingent on irregular milestone or financing events. A small and unpredictable revenue base cannot cover R&D or G&A sustainably, increasing reliance on external deals and creating long‑term operating uncertainty.
Atai Beckley N.V. News
B72 FAQ
What was Atai Beckley N.V.’s price range in the past 12 months?
Atai Beckley N.V. lowest stock price was €1.19 and its highest was €6.00 in the past 12 months.
What is Atai Beckley N.V.’s market cap?
Atai Beckley N.V.’s market cap is €1.32B.
When is Atai Beckley N.V.’s upcoming earnings report date?
Atai Beckley N.V.’s upcoming earnings report date is May 20, 2026 which is in 15 days.
How were Atai Beckley N.V.’s earnings last quarter?
Currently, no data Available
Is Atai Beckley N.V. overvalued?
According to Wall Street analysts Atai Beckley N.V.’s price is currently Undervalued.
Does Atai Beckley N.V. pay dividends?
Atai Beckley N.V. does not currently pay dividends.
What is Atai Beckley N.V.’s EPS estimate?
Atai Beckley N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atai Beckley N.V. have?
Atai Beckley N.V. has 366,916,900 shares outstanding.
What happened to Atai Beckley N.V.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Atai Beckley N.V.?
Currently, no hedge funds are holding shares in DE:B72
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atai Beckley N.V. Stock Smart Score
Company Description
Atai Beckley N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.
B72 Stock 12 Month Forecast
Average Price Target
€12.66
▲(247.92% Upside)
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
―
Praxis Precision Medicines
―
Options Prices
Currently, No data available
---